Urokinase receptor, MMP-1 and MMP-9 are markers to differentiate prognosis, adenoma and carcinoma in thyroid malignancies

International Journal of Cancer

Volumn 125, Issue 4, 2009, Pages 894-901

  Buergy, Daniel ^a   Weber, Theresia ^b   Maurer, Gabriele D ^a   Mudduluru, Giridhar ^a   Medved, Fabian ^a   Leupold, Joerg H ^a   Brauckhoff, Michael ^c   Post, Stefan ^a   Dralle, Henning ^c   Allgayer, Heike ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b UNIVERSITY OF ULM   (Germany)

^c MARTIN LUTHER UNIVERSITY HALLE WITTENBERG   (Germany)

Author keywords

MMPs; Thyroid adenoma; Thyroid carcinoma; u PAR

Indexed keywords

GELATINASE B; INTERSTITIAL COLLAGENASE; TRANSCRIPTION FACTOR; UROKINASE RECEPTOR;

ARTICLE; CANCER DIAGNOSIS; CANCER STAGING; CONTROLLED STUDY; DIFFERENTIAL DIAGNOSIS; DISEASE ASSOCIATION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FOLLICULAR CARCINOMA; GEL MOBILITY SHIFT ASSAY; GENE EXPRESSION; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; MEDULLARY CARCINOMA; PRIORITY JOURNAL; PROGNOSIS; STATISTICAL SIGNIFICANCE; THYROID ADENOMA; THYROID CARCINOMA;

ADENOCARCINOMA, FOLLICULAR; ADENOMA; ADULT; AGED; BLOTTING, WESTERN; CARCINOMA, PAPILLARY; ELECTROPHORETIC MOBILITY SHIFT ASSAY; FEMALE; HUMANS; IMMUNOENZYME TECHNIQUES; LUCIFERASES; MALE; MATRIX METALLOPROTEINASE 1; MATRIX METALLOPROTEINASE 7; MATRIX METALLOPROTEINASE 9; MIDDLE AGED; PROGNOSIS; PROMOTER REGIONS, GENETIC; RECEPTORS, UROKINASE PLASMINOGEN ACTIVATOR; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; THYROID NEOPLASMS; TRANSFECTION; TUMOR MARKERS, BIOLOGICAL;

EID: 67650136108     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.24462     Document Type: Article

References (44)

1. Mazzaferri EL. Management of a solitary thyroid nodule. N Engl J Med 1993;328:553-9.
2. Reiners C, Schumm-Draeger PM, Geling M, Mastbaum C, Schonberger J, Laue-Savic A, Hackethal K, Hampel R, Heinken U, Kullak W, Linke R, Uhde W. [Thyroid gland ultrasound screening (Papillon Initiative). Report of 15 incidentally detected thyroid cancers]. Internist (Berl) 2003;44:412-19.
3. Jemal A, Siegel R, Ward E, Murray T, Xu J, Smigal C, Thun MJ. Cancer statistics, 2006. CA Cancer J Clin 2006;56:106-30.
4. Elisei R, Bottici V, Luchetti F, Di Coscio G, Romei C, Grasso L, Miccoli P, Iacconi P, Basolo F, Pinchera A, Pacini F. Impact of routine measurement of serum calcitonin on the diagnosis and outcome of medullary thyroid cancer: experience in 10,864 patients with nodular thyroid disorders. J Clin Endocrinol Metab 2004;89: 163-8.
5. Hundahl SA, Fleming ID, Fremgen AM, Menck HR. A National Cancer Data Base report on 53,856 cases of thyroid carcinoma treated in the U.S. Cancer 1998;83:2638-48.
6. Passler C, Scheuba C, Prager G, Kaczirek K, Kaserer K, Zettinig G, Niederle B. Prognostic factors of papillary and follicular thyroid cancer: differences in an iodine-replete endemic goiter region. Endocr Relat Cancer 2004;11:131-9.
7. Quayle FJ, Benveniste R, DeBenedetti MK, Wells SA, Moley JF. Hereditary medullary thyroid carcinoma in patients greater than 50 years old. Surgery 2004;136:1116-21.
8. Ukkat J, Gimm O, Brauckhoff M, Bilkenroth U, Dralle H. Single center experience in primary surgery for medullary thyroid carcinoma. World J Surg 2004;28:1271-4.
9. Weber T, Schilling T, Frank-Raue K, Colombo-Benkmann M, Hinz U, Ziegler R, Klar E. Impact of modified radical neck dissection on biochemical cure in medullary thyroid carcinomas. Surgery 2001;130:1044-9.
10. Ain KB. Anaplastic thyroid carcinoma: behavior, biology, and therapeutic approaches. Thyroid 1998;8:715-26.
11. Blasi F. Urokinase and urokinase receptor: a paracrine/autocrine system regulating cell migration and invasiveness. Bioessays 1993;15:105-11.
12. Kim J, Yu W, Kovalski K, Ossowski L. Requirement for specific proteases in cancer cell intravasation as revealed by a novel semiquantitative PCR-based assay. Cell 1998;94:353-62.
13. Berman MB. Regulation of corneal fibroblast MMP-1 collagenase secretion by plasmin. Cornea 1993;12:420-32.
14. Davis GE, Pintar Allen KA, Salazar R, Maxwell SA. Matrix metalloproteinase-1 and -9 activation by plasmin regulates a novel endothelial cell-mediated mechanism of collagen gel contraction and capillary tube regression in three-dimensional collagen matrices. J Cell Sci 2001;114:917-30.
15. Imai K, Yokohama Y, Nakanishi I, Ohuchi E, Fujii Y, Nakai N, Okada Y. Matrix metalloproteinase 7 (matrilysin) from human rectal carcinoma cells. Activation of the precursor, interaction with other matrix metalloproteinases and enzymic properties. J Biol Chem 1995;270:6691-7.
16. Hahn-Dantona E, Ramos-DeSimone N, Sipley J, Nagase H, French DL, Quigley JP. Activation of proMMP-9 by a plasmin/MMP-3 cascade in a tumor cell model. Regulation by tissue inhibitors of metalloproteinases. Ann N Y Acad Sci 1999;878:372-87.
17. Ramos-DeSimone N, Hahn-Dantona E, Sipley J, Nagase H, French DL, Quigley JP. Activation of matrix metalloproteinase-9 (MMP-9) via a converging plasmin/stromelysin-1 cascade enhances tumor cell invasion. J Biol Chem 1999;274:13066-76.
18. Legrand C, Polette M, Tournier JM, de Bentzmann S, Huet E, Monteau M, Birembaut P. uPA/plasmin system-mediated MMP-9 activation is implicated in bronchial epithelial cell migration. Exp Cell Res 2001;264:326-36.
19. Morgan H, Hill PA. Human breast cancer cell-mediated bone collagen degradation requires plasminogen activation and matrix metalloproteinase activity. Cancer Cell Int 2005;5:1.
20. Schewe DM, Biller T, Maurer G, Asangani IA, Leupold JH, Lengyel ER, Post S, Allgayer H. Combination analysis of activator protein-1 family members. Sp1 and an activator protein-2α-related factor binding to different regions of the urokinase receptor gene in resected colorectal cancers. Clin Cancer Res 2005;11:8538-48.
21. Maurer GD, Leupold JH, Schewe DM, Biller T, Kates RE, Hornung HM, Lau-Werner U, Post S, Allgayer H. Analysis of specific transcriptional regulators as early predictors of independent prognostic relevance in resected colorectal cancer. Clin Cancer Res 2007;13:1123-32.
22. Pedersen H, Brunner N, Francis D, Osterlind K, Ronne E, Hansen HH, Dano K, Grondahl-Hansen J. Prognostic impact of urokinase, urokinase receptor, and type 1 plasminogen activator inhibitor in squamous and large cell lung cancer tissue. Cancer Res 1994;54:4671-5.
23. Mulcahy HE, Duffy MJ, Gibbons D, McCarthy P, Parfrey NA, O'Donoghue DP, Sheahan K. Urokinase-type plasminogen activator and outcome in Dukes' B colorectal cancer. Lancet 1994;344:583-4.
24. Ganesh S, Sier CF, Heerding MM, Griffioen G, Lamers CB, Verspaget HW. Urokinase receptor and colorectal cancer survival. Lancet 1994;344:401-2.
25. Nekarda H, Schmitt M, Ulm K, Wenninger A, Vogelsang H, Becker K, Roder JD, Fink U, Siewert JR. Prognostic impact of urokinase-type plasminogen activator and its inhibitor PAI-1 in completely resected gastric cancer. Cancer Res 1994;54:2900-7.
26. Heiss MM, Allgayer H, Gruetzner KU, Funke I, Babic R, Jauch KW, Schildberg FW. Individual development and uPA-receptor expression of disseminated tumour cells in bone marrow: a reference to early systemic disease in solid cancer. Nat Med 1995;1:1035-9.
27. Allgayer H, Heiss MM, Riesenberg R, Grutzner KU, Tarabichi A, Babic R, Schildberg FW. Urokinase plasminogen activator receptor (uPA-R): one potential characteristic of metastatic phenotypes in minimal residual tumor disease. Cancer Res 1997;57:1394-9.
28. Beyer BC, Heiss MM, Simon EH, Gruetzner KU, Babic R, Jauch KW, Schildberg FW, Allgayer H. Urokinase system expression in gastric carcinoma: prognostic impact in an independent patient series and first evidence of predictive value in preoperative biopsy and intestinal metaplasia specimens. Cancer 2006;106:1026-35.
29. Kim SJ, Shiba E, Taguchi T, Tsukamoto F, Miyoshi Y, Tanji Y, Takai S, Noguchi S. uPA receptor expression in benign and malignant thyroid tumors. Anticancer Res 2002;22:387-93.
30. Cho Mar K, Eimoto T, Tateyama H, Arai Y, Fujiyoshi Y, Hamaguchi M. Expression of matrix metalloproteinases in benign and malignant follicular thyroid lesions. Histopathology 2006;48:286-94.
31. Patel A, Straight AM, Mann H, Duffy E, Fenton C, Dinauer C, Tuttle RM, Francis GL. Matrix metalloproteinase (MMP) expression by differentiated thyroid carcinoma of children and adolescents. J Endocrinol Invest 2002;25:403-8.
32. Schewe DM, Leupold JH, Boyd DD, Lengyel ER, Wang H, Gruetzner KU, Schildberg FW, Jauch KW, Allgayer H. Tumor-specific transcription factor binding to an activator protein-2/Sp1 element of the urokinase-type plasminogen activator receptor promoter in a first large series of resected gastrointestinal cancers. Clin Cancer Res 2003;9:2267-76.
33. Shetty S, Idell S. A urokinase receptor mRNA binding protein-mRNA interaction regulates receptor expression and function in human pleural mesothelioma cells. Arch Biochem Biophys 1998;356:265-79.
34. Montuori N, Rossi G, Ragno P. Cleavage of urokinase receptor regulates its interaction with integrins in thyroid cells. FEBS Lett 1999;460:32-6.
35. Riesco-Eizaguirre G, Santisteban P. New insights in thyroid follicular cell biology and its impact in thyroid cancer therapy. Endocr Relat Cancer 2007;14:957-77.
36. Patel KN, Singh B. Genetic considerations in thyroid cancer. Cancer Control 2006;13:111-18.
37. Gollner H, Bouwman P, Mangold M, Karis A, Braun H, Rohner I, Del Rey A, Besedovsky HO, Meinhardt A, van den Broek M, Cutforth T, Grosveld F, et al. Complex phenotype of mice homozygous for a null mutation in the Sp4 transcription factor gene. Genes Cells 2001;6:689-97.
38. Miyata Y, Iwata T, Ohba K, Kanda S, Nishikido M, Kanetake H. Expression of matrix metalloproteinase-7 on cancer cells and tissue endothelial cells in renal cell carcinoma: prognostic implications and clinical significance for invasion and metastasis. Clin Cancer Res 2006;12:6998-7003.
39. Ito Y, Yoshida H, Kakudo K, Nakamura Y, Kuma K, Miyauchi A. Inverse relationships between the expression of MMP-7 and MMP-11 and predictors of poor prognosis of papillary thyroid carcinoma. Pathology 2006;38:421-5.
40. Egeblad M, Werb Z. New functions for the matrix metalloproteinases in cancer progression. Nat Rev Cancer 2002;2:161-74.
41. Sun CF, Wu TL, Tsao KC, Wu JT. Development of two ELISA for estrogen and progesterone receptor with sufficient sensitivity for fine needle aspirate and core biopsy. J Clin Lab Anal 2001;15:138-43.
42. Daud AI, DeConti RC, Andrews S, Urbas P, Riker AI, Sondak VK, Munster PN, Sullivan DM, Ugen KE, Messina JL, Heller R. Phase I trial of interleukin-12 plasmid electroporation in patients with metastatic melanoma. J Clin Oncol 2008;26:5896-903.
43. Krishnamurthy S. Applications of molecular techniques to fine-needle aspiration biopsy. Cancer 2007;111:106-22.
44. Mora J, Lerma E. Telomerase activity in thyroid fine needle aspirates. Acta Cytol 2004;48:818-24.